Antibody Profiling by Proteome Microarray Reveals the Immunogenicity of the Attenuated Smallpox Vaccine Modified Vaccinia Virus Ankara Is Comparable to That of Dryvax

Development of vaccinia virus antibodies in hyperimmunized rabbits. Two groups of rabbits were inoculated with MVA or WR to generate hyperimmune sera, as shown in Fig. 1A. (A) Serum antibody titers of individual rabbits inoculated with MVA or WR were determined by whole-virus ELISA. Shown are average titers (± SD) of three rabbits in each group. (B) Neutralization titers were determined by incubation of twofold serial dilutions of sera with a recombinant vaccinia virus that expresses enhanced GFP and then quantifying infected cells by flow cytometry. Shown are average (Avg) neutralization titers (± SD) of three rabbits in each group. IC₅₀, 50% inhibitory concentration.

Comparable data obtained by ELISA and by protein microarray for four signature membrane proteins. (A) ELISAs of rabbit hyperimmune WR and MVA sera by use of plates coated with baculovirus-expressed vaccinia virus proteins. MV membrane proteins were represented by L1 and A27 and EV proteins by B5 and A33. (B) Corresponding SIs revealed by proteome microarrays probed with the same hyperimmune rabbit sera as used for the ELISAs in panel A. L1ss, L1 expressed in RTS disulfide kits (see text for details); avg, average.

Rabbit hyperimmune MVA sera predominantly contain antibodies to late virion proteins, whereas WR is pathogenic in rabbits and also induces antibodies to early proteins. Hyperimmune rabbit sera generated against MVA (A) and WR (B) according to the schedules shown in Fig. 1A were used to probe WR proteome microarrays. The “no-DNA” control signals were subtracted from the SI for each protein and assigned a shade of color according to the strength of the signal, shown at the bottom of the figure. Antigens that were uniformly seronegative (i.e., SI of <5,000 in all six animals) have been omitted for clarity. The antigens have been classified into main groups 1 to 4 as follows. Group 1 consists of structural proteins, which have been subclassified into membrane proteins on intracellular MV and EV, core proteins, and other virion-associated late proteins. Group 2 consists of regulation proteins, subclassified into “transcr.” (transcription, translation) and “replic.” (DNA synthesis and genome replication). Group 3 consists of host range, virulence, and host defense proteins (virokines, cytokine receptors, and modulators of apoptosis, etc.). Group 4 consists of proteins of unknown function. Promoter designations (from www.poxvirus.org ): L, late; E/L, early/late; E, early. (C) Virion proteins determined by mass spectroscopy studies of WR virions are indicated by the filled cells; data in columns a to c are from references 8, 28, and 38, respectively.

Titers to some anti-MV antibodies are lower for hyperimmune MVA sera than for hyperimmune WR sera. (A) Sera from rabbits taken at the final time point (Fig. 1A) were serially diluted and used to probe vaccinia virus protein microarrays. Shown are titration curves for H3; average “no-DNA” control signals were subtracted from all SIs. (B) Average antibody titers (+ 1 SD) against MV and EV membrane proteins only. Titers were determined from titration plots by interpolating from the inflection point. *, Significant difference between MVA and WR responses by two-tailed, paired t test (P < 0.05). L1ss, L1 expressed in RTS disulfide kits (see text for details); avg, average.

Antibody profiling of macaques inoculated with MVA or Dryvax shows both profiles are dominated by antibodies to structural proteins. Antibody profiles of cynomolgus macaques pre- and postimmunization with MVA/MVA (n = 6) (A), MVA/DVX (n = 6) (B), or −/DVX (n = 6) (C) according to the schedules shown in Fig. 1B. Note that week 14 of the Dryvax-alone experiment (C) corresponds to week 6 postvaccination (Fig. 1B). Data representation is as described for Fig. 4. (D) Virion proteins determined by mass spectroscopy studies of WR virions are indicated by the filled cells; data in columns a to c are from references 8, 28, and 38, respectively.

Antibody profiling of humans inoculated with MVA or Dryvax (DVX) shows both profiles are dominated by antibodies to structural proteins. Antibody profiles for humans pre- and postvaccination with MVA (A) and WR (B) according to the schedule shown in Fig. 1C. Data representation is as described for Fig. 4. For Dryvax responses, primary (n = 13) and secondary (n = 12) infections are shown. (C) Virion proteins determined by mass spectroscopy studies of WR virions are indicated by the filled cells; data in columns a to c are from references 8, 28, and 38, respectively. The B2 antigen was consistently recognized by vaccinia virus-naïve human IgG, although this was nonspecific and independent of vaccination.

Summary of antibody profiles for humans and macaques. Humans and macaques were inoculated with Dryvax (DVX) or MVA according to the schedules shown in Fig. 1. Bars represent average SIs (+ SD) of the top-ranking antigens for all four cohorts combined: gray bars, prevaccination; black bars, postvaccination. (A) Macaque responses, pre- and 14 weeks post-MVA (“MVA/MVA” in Fig. 1B; n = 6). (B) Macaque responses pre- and 6 weeks post-Dryvax (“−/DVX” in Fig. 1B; n = 6). (C) Human responses pre- and 6 weeks post-MVA (n = 10). (D) Human responses pre- and 4 weeks post-Dryvax (n = 25). This last panel consisted of 13 individuals undergoing primary responses and 12 individuals after boosting. Positive signals in prevaccination signals in the human/Dryvax group (e.g., H3, A10, and WR148) are due to antibodies still detectable in the sera of previously vaccinated individuals (n = 12); a cutoff, represented by the horizontal bar, was set as the average signal (+ 10 SD) of “no-DNA” control spots with postvaccination sera.